Investigating the roles for UHRF1 in RB cells in response to HDAC inhibitors may provide a novel insight into the eligibility of UHRF1 as a potential target whose downmodulation can sensitize the cells to HDAC inhibitors as is the case with conventional chemotherapeutic drugs. The gene discussed is HDAC9; the disease is retinoblastoma.